文献速递基础与转化研究临床试验与 GCP新药、器械与细胞基因治疗研发

靶向C3b/C4b与VEGF的双特异性融合蛋白经优化用于新生血管性年龄相关性黄斑变性治疗

Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy.
PubMed 文献 · Sci Transl Med · 2022-06-01

本研究报道双特异性融合蛋白efdamrofusp alfa(IBI302)的临床前评估及1期临床结果,该蛋白可中和VEGF异构体与C3b/C4b。小鼠激光诱导脉络膜新生血管模型中玻璃体腔给药疗效优于抗VEGF单药治疗,并进一步抑制巨噬细胞浸润与M2极化。非人灵长类模型显示良好安全性与抗血管生成疗效,1期剂量递增试验(NCT03814291)初步显示nAMD患者耐受良好。

要点

  • efdamrofusp alfa可同时中和VEGF异构体与C3b/C4b。
  • 小鼠激光诱导CNV模型中疗效优于抗VEGF单药治疗。
  • 1期剂量递增试验中nAMD患者耐受良好。

核心结论

  • efdamrofusp alfa可能对治疗nAMD有效,并可能对其他补体相关眼部疾病有效。

研究设计与样本

  • 临床前评估包括小鼠激光诱导脉络膜新生血管模型和非人灵长类激光诱导CNV模型。
  • 基于临床前数据开展1期剂量递增临床试验(NCT03814291)。

主要发现

  • efdamrofusp alfa在小鼠激光诱导CNV模型玻璃体腔给药后疗效优于抗VEGF单药治疗。
  • VEGF与补体激活双重抑制进一步抑制巨噬细胞浸润和M2巨噬细胞极化。
  • 玻璃体腔注射efdamrofusp alfa在非人灵长类激光诱导CNV模型中显示良好安全性特征和抗血管生成疗效。
  • 1期试验初步结果显示efdamrofusp alfa在nAMD患者中耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antiangiogenesis therapies targeting vascular endothelial growth factor (VEGF) have revolutionized the treatment of neovascular ocular diseases, including neovascular age-related macular degeneration (nAMD). Compelling evidence has implicated the vital role of complement system dysregulation in AMD pathogenesis, implying it as a potential therapeutic strategy for geographic atrophy in dry AMD and to enhance the efficacy of anti-VEGF monotherapies in nAMD. This study reports the preclinical assessment and phase 1 clinical outcomes of a bispecific fusion protein, efdamrofusp alfa (code: IBI302), which is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa showed superior efficacy over anti-VEGF monotherapy in a mouse laser-induced choroidal neovascularization (CNV) model after intravitreal delivery. Dual inhibition of VEGF and the complement activation was found to further inhibit macrophage infiltration and M2 macrophage polarization. Intravitreal efdamrofusp alfa demonstrated favorable safety profiles and exhibited antiangiogenetic efficacy in a nonhuman primate laser-induced CNV model. A phase 1 dose-escalating clinical trial (NCT03814291) was thus conducted on the basis of the preclinical data. Preliminary results showed that efdamrofusp alfa was well tolerated in patients with nAMD. These data suggest that efdamrofusp alfa might be effective for treating nAMD and possibly other complement-related ocular conditions.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Yang S, Li T, Jia H, et al. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Sci Transl Med. 2022. PMID: 35648811. doi:10.1126/scitranslmed.abj2177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。